Anhedonia, Development, and Emotions: Phenotyping and Therapeutics (ADEPT) Study
This study is sponsored by the Wellcome Leap: Multi-Channel Psych Program
The goal of the ADEPT Study is to understand anhedonia in young people and how it changes based on treatments targeting the brain circuit underlying it. Anhedonia is a challenging mental health symptom that involves difficulty with motivation to experience pleasant events. This study could help develop treatments for people whose depression does not improve with traditional treatments. IRB: STUDY21120080, ClinicalTrials.gov: NCT05487885
The ADEPT Study includes two phases:
- Phase 1 includes a series of activities to measure anhedonia, including an MRI scan, blood draw, behavioral task, clinical interview, questionnaires, and app-based assessments of experiences and behaviors.
- Phase 2 involves therapeutic activities, such as transcranial magnetic stimulation (TMS), positive affect training, and, for some people, ketamine administration.
If you're interested, please take this short survey or scan here:
Current Collaborators
- Kristen Eckstrand, MD, PhD - University of Pittsburgh
- Neil Jones, PhD - University of Pittsburgh
- Helmet Karim, PhD - University of Pittsburgh, The Geriatric Psychiatry Neuroimaging (GPN) Lab
- Jihui Lee, PhD - University of Pittsburgh
- Bea Luna, PhD - University of Pittsburgh, The Laboratory of Neurocognitive Development (LNCD)
- Rebecca Price, PhD - University of Pittsburgh, The Clinical Application of Neuroscience (CAN) Lab
- Neal Ryan, MD - University of Pittsburgh